DigestRedComo funciona
Red
/
Empresas
Co
No verificado

Corcept Therapeutics Incorporated

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

30 Comunicados de prensa

Ver todos los comunicados de prensa
22/01/2026
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Medicina - Varios
Industria
Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
Fuente
Corcept Therapeutics Incorporated
Editor
Business Wire
1.00
0
31/12/2026
Farmacéutica
Oncología
Comunicación
Sanidad
Salud
Higiene alimentaria
Industria
Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism
Fuente
Corcept Therapeutics Incorporated
Editor
Business Wire
1.00
0
04/11/2025
Web y redes sociales
Telefonía
Mercado de valores
Higiene alimentaria
Biotecnología
Salud
Medicina - Varios
Sanidad
Farmacéutica
Oncología
Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update
Fuente
Corcept Therapeutics Incorporated
Editor
Business Wire
1.00
0
28/10/2025
Sanidad
Farmacéutica
Salud
Medicina - Varios
Web y redes sociales
Telefonía
Finanzas
Mercado de valores
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
Fuente
Corcept Therapeutics Incorporated
Editor
Business Wire
1.00
0
19/10/2025
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Eventos
Industria
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment
Fuente
Corcept Therapeutics Incorporated
Editor
Business Wire
1.00
0
14/10/2025
Ciencia
Medicina - Varios
Biotecnología
Sanidad
Salud
Farmacéutica
Oncología
Industria
Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
Fuente
Corcept Therapeutics Incorporated
Editor
Business Wire
1.00
0
22/09/2025
Eventos
Ferias y Congresos
Industria
Ciencia
Biotecnología
Medicina - Varios
Salud
Farmacéutica
Sanidad
Oncología
Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025
Fuente
Corcept Therapeutics Incorporated
Editor
Business Wire
1.00
0
10/09/2025
Oncología
Higiene alimentaria
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Industria
FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
Fuente
Corcept Therapeutics Incorporated
Editor
Business Wire
1.00
0
31/07/2025
Material médico sanitario
Higiene alimentaria
Medicina - Varios
Sanidad
Biotecnología
Farmacéutica
Salud
Oncología
Web y redes sociales
Telefonía
Mercado de valores
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
Fuente
Corcept Therapeutics Incorporated
Editor
Business Wire
1.00
0
24/07/2025
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Web y redes sociales
Telefonía
Finanzas
Mercado de valores
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
Fuente
Corcept Therapeutics Incorporated
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0